Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.2% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a company in the gene editing industry that has been receiving mixed ratings from analysts and experiencing fluctuations in its stock performance.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.2% on Mar 31, 2026 14:05

• Despite receiving a "Hold" rating from most brokerages, Intellia Therapeutics experienced a significant uptrend after being upgraded to a "strong-buy" by Truist Financial.
• The gene editing sector, including Intellia Therapeutics, faced a downtrend, possibly influencing the stock price initially.
• Intellia Therapeutics' recent strong earnings report, surpassing expectations, likely boosted investor confidence in its performance.
• The internal reshuffling of Vanguard's holdings, resulting in share disaggregation, may have caused some uncertainty but did not have a direct impact on the stock movement.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received a consensus "Hold" rating from twenty brokerages, with an average 12-month price target of $19.59. Despite the company beating EPS and revenue estimates in its latest quarter, it remains unprofitable, with analysts forecasting a negative EPS for the current year. Insider selling occurred last quarter, while institutional investors hold a significant majority of the stock.

https://www.marketbeat.com/instant-alerts/intellia-therapeutics-inc-nasdaqntla-receives-consensus-rating-of-hold-from-brokerages-2026-03-31/

Trending Industry Today: Intellia Therapeutics Leads Losses In Gene Editing Stocks

This article reports on the trending gene editing industry, highlighting that Intellia Therapeutics is leading the losses among gene editing stocks. The content indicates a negative trend within this specific sector.

https://www.moomoo.com/news/post/67562231/trending-industry-today-intellia-therapeutics-leads-losses-in-gene-editing

Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares

The Vanguard Group has filed an amended Schedule 13G/A for Intellia Therapeutics (NTLA), reporting 0 shares and 0% beneficial ownership. This change is due to an internal realignment that disaggregates holdings to its subsidiaries, meaning Vanguard itself no longer formally beneficially owns these securities. The filing indicates that subsidiaries will now report their ownership separately, affecting only the reporting structure, not the underlying investment strategy.

https://www.stocktitan.net/sec-filings/NTLA/schedule-13g-a-intellia-therapeutics-inc-amended-passive-investment-d-438e2006716c.html

Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Strong-Buy at Truist Financial

Truist Financial has upgraded Intellia Therapeutics (NASDAQ:NTLA) to a "strong-buy" rating. Despite this, the MarketBeat consensus remains a "Hold" with a $19.59 price target. The company recently exceeded quarterly earnings and revenue expectations, but some insiders have sold shares.

https://www.marketbeat.com/instant-alerts/intellia-therapeutics-nasdaqntla-rating-increased-to-strong-buy-at-truist-financial-2026-03-26/

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Lemonda Inc. ($LMND) Stock Forecast: Down 5.6% Today

Exxon Mobil Corporation ($XOM) Stock Forecast: Down 5.0% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Up 5.7% Today

Intel Corporation ($INTC) Stock Forecast: Up 8.8% Today

Alexandria Real Estate Equities Inc. ($ARE) Stock Forecast: Down 6.9% Today

Hasbro Inc. ($HAS) Stock Forecast: Down 5.1% Today

Alcoa Corporation ($AA) Stock Forecast: Up 8.3% Today

The Boeing Company ($BA) Stock Forecast: Up 5.1% Today

Groupon Inc. ($GRPN) Stock Forecast: Down 5.2% Today

Intellia Therapeutics, Inc. Price History

26.01.2026 - NTLA Stock was up 10.7%

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

31.02.2026 - NTLA Stock was up 5.2%

• Despite receiving a "Hold" rating from most brokerages, Intellia Therapeutics experienced a significant uptrend after being upgraded to a "strong-buy" by Truist Financial.
• The gene editing sector, including Intellia Therapeutics, faced a downtrend, possibly influencing the stock price initially.
• Intellia Therapeutics' recent strong earnings report, surpassing expectations, likely boosted investor confidence in its performance.
• The internal reshuffling of Vanguard's holdings, resulting in share disaggregation, may have caused some uncertainty but did not have a direct impact on the stock movement.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

05.02.2026 - NTLA Stock was down 5.1%

• Despite recent positive developments, such as analyst upgrades, strong financial results, and progress with its Phase 3 trial after regulatory hurdles were resolved, Intellia Therapeutics saw a decline in its stock price.
• The market response may have been influenced by the company's decision to expand its At-The-Market offering program to $1.04 billion, which could potentially lead to dilution of existing shares and impact shareholder value.
• Concerns regarding the company's financial performance, such as negative margins and a high valuation, despite advancements in its pipeline and clinical work, might have unsettled investors.
• The divergence in opinions among analysts and the uncertainty surrounding Intellia's path to profitability likely contributed to the negative market sentiment, even amidst positive strides in its therapeutic initiatives.

03.02.2026 - NTLA Stock was down 5.1%

• The stock price of Intellia Therapeutics plummeted despite recent positive developments and analyst upgrades, indicating a possible case of "buy the rumor, sell the news" behavior among investors.
• The FDA's decision to lift the clinical hold on the MAGNITUDE Phase 3 trial for a key therapy was initially seen as a positive development, but concerns over the safety and efficacy of the treatment may have led to the market's negative reaction.
• The company's decision to increase its At-The-Market offering program to $1.04 billion could have also contributed to the bearish sentiment, signaling potential dilution of existing shares and impacting shareholder value.
• Overall, the market movement suggests that investors may be exercising caution and reevaluating their positions in Intellia Therapeutics amidst a mix of positive news and financial decisions by the company.

24.01.2026 - NTLA Stock was up 5.7%

• The development of an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis through CRISPR/Cas9 technology has likely spurred investor optimism and interest in Intellia Therapeutics.
• Encouraging reduction in harmful protein production observed in early clinical trial findings could pave the way for advancements in treating genetic disorders, potentially enhancing the company's standing and stock performance.
• Noteworthy institutional investments, such as those from Jupiter Asset Management Ltd. amounting to $23.52 million, signal increasing confidence in Intellia Therapeutics' future prospects and may have influenced the recent positive market trend.
• Anticipation surrounding an imminent conference call to discuss financial results and business updates could be fueling positive investor sentiment and driving up the stock price.

19.02.2026 - NTLA Stock was down 5.4%

• Farallon Capital Management LLC acquired a significant number of shares in NTLA, indicating confidence in the company's potential.
• Despite reporting better-than-expected earnings and surpassing analyst revenue estimates, company insiders have been selling shares in the last ninety days.
• The increased holdings by institutional investors may have contributed to the downward pressure on NTLA's stock price.
• The bearish movement could be a result of profit-taking by insiders or concerns about the sustainability of NTLA's recent positive performance.

19.01.2026 - NTLA Stock was up 6.3%

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

25.02.2026 - NTLA Stock was up 5.3%

• The rise in NTLA's stock price might be due to positive sentiment from AI models suggesting short-term strength and the adoption of potential institutional trading strategies.
• Despite recent selling by Hudson Bay Capital Management LP and company insiders, the stock surpassed Q3 revenue and EPS estimates, indicating solid fundamentals.
• A possible securities class action lawsuit alleging lack of disclosure on the inefficiency of the NTLA-3001 program initially led to a stock price decline, but investors appear hopeful about the company's future prospects.
• In summary, the surge in Intellia Therapeutics' stock price today could be driven by a blend of positive sentiment, exceeding financial expectations, and potential institutional trading strategies.

27.01.2026 - NTLA Stock was up 5.2%

• Intellia Therapeutics (NTLA) reported a Q4 loss of $0.83 per share, but exceeded revenue estimates, indicating strong potential for revenue growth.
• The positive momentum was driven by an earnings beat, promising trial data for hereditary angioedema, and the release of an FDA clinical hold, boosting investor confidence in the company's pipeline.
• The stock's valuation narrative is mixed, with discussions about high current multiples but substantial undervaluation based on future revenue potential, emphasizing the significance of upcoming milestones such as the Phase 3 HAELO trial for future growth.
• Despite recent share price increases, the company's three-year return is negative, signaling investor optimism about Intellia Therapeutics' long-term prospects despite some short-term obstacles.

02.02.2026 - NTLA Stock was up 5.6%

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.

11.02.2026 - NTLA Stock was down 7.9%

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.